COMP <GO>
OPCH vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Option Care Health Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: OPCH 6
— ABBV 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $31.83 (-0.06%) • MKT CAP: $4.77B
roic
11.90%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OPCH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OPCH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.30% | 70.20% | -50.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 11.90% | 29.00% | -17.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.3x | 33.3x | -18.00 | OPCH | /valuation <GO> |
| Free Cash Flow Yield | 4.55% | 3.47% | +1.08 | OPCH | /fcf-yield <GO> |
| Operating Margin | 6.00% | 24.60% | -18.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 6.90% | -3.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 13.00% | 8.60% | +4.40 | OPCH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.81 | 5.33 | -1.52 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | OPCH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 84.3 | 72.8 | +11.48 | OPCH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.15 | -0.05 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.3x | 113.1x | -93.80 | OPCH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.77B | $513.86B | -$509.09B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OPCH REV | ABBV REV | OPCH GROSS % | ABBV GROSS % | OPCH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.65B | $61.16B | 19.3% | 70.2% | $217.1M | $17.82B |
| FY 2024 | $5.00B | $56.33B | 20.3% | 70.0% | $287.8M | $17.83B |
| FY 2023 | $4.30B | $54.32B | 44.0% | 44.0% | $177.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OPCH // BETA 1.10
ABBV // BETA 1.15